Co-Chairs, Nasser Altorki, MD, and Jonathan D. Spicer, MD, PhD, FRCSC, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC activity titled “Can the Addition of Immunotherapy to Multimodal Management of Stage I-III NSCLC Help Break the Stalled Cycle of Poor Outcomes?” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/3m1OV2m. CME/MOC credit will be available until February 27, 2023.
Co-Chairs, Nasser Altorki, MD, and Jonathan D. Spicer, MD, PhD, FRCSC, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC activity titled “How to Integrate Perioperative Immunotherapy Into Multimodal Treatment Plans to Improve Outcomes in Resectable NSCLC.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/3xb6WS1. CME/MOC credit will be available until June 14, 2023.
Chair & Moderator, Prof. Solange Peters, MD, PhD, Mark M. Awad, MD, PhD, and Jonathan D. Spicer, MD, PhD, FRCSC, prepared useful Practice Aids pertaining to Cancer Immunotherapy for this CME/MOC/CC activity titled “Parsing the Practicalities of Pathologic Response Assessment After Neoadjuvant Immunotherapy to Facilitate Progress in Early-Stage Cancers.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/CC information, and to apply for credit, please visit us at https://bit.ly/3uRHyjk. CME/MOC/CC credit will be available until May 9, 2023.
Robert Anders, MD, PhD, Julie R. Brahmer, MD, MSc, and Christopher D. Gocke, MD, prepared useful Practice Aids pertaining to immunotherapy and biomarker testing for this CME/MOC/CC activity titled "Keeping Up With Advances in Cancer Immunotherapy and Biomarker Testing: Implications for Pathologists at the Forefront of the Emerging Precision Immuno-Oncology Era." For the full presentation, monograph, complete CME/MOC/CC information, and to apply for credit, please visit us at http://bit.ly/2L7zlSy. CME/MOC/CC credit will be available until May 2, 2020.
Co-Chairs and Presenter Jessica Donington, MD, Jonathan D. Spicer, MD, PhD, FRCSC, and Patrick M. Forde, MD, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC/CC/AAPA activity titled “A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant and/or Adjuvant Immunotherapy in Resectable NSCLC.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at https://bit.ly/3MQVu5l. CME/MOC/CC/AAPA credit will be available until February 27, 2025.
This is a brief overview of the evolving field of prophylactic and therapeutic cancer vaccines.
Cancer vaccines are active immunotherapies. As seen in the accompanying figure, the distinction from passive immunotherapies is based on different mechanisms of action. Passive immunotherapies and adoptive T-cell transfer, for example, are made/modified outside of the body.
Once inside the body they can compensate for missing or deficient functions. Active immunotherapies, on the other hand, stimulate effector functions in vivo. What this means, is that the patient’s immune system can respond to the challenge and be stimulated to mediate effector cells that defend the body in an immune response. Examples of active immunotherapies include peptide, dendritic cell, and allogeneic whole-cell vaccines.
This intro is geared towards interested novices who wish to find a resource that can serve as a starting point for further self-study. This is not meant to replace a doctor's advice. Please approach a medical professional for any health condition.
Co-Chairs, Nasser Altorki, MD, and Jonathan D. Spicer, MD, PhD, FRCSC, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC activity titled “How to Integrate Perioperative Immunotherapy Into Multimodal Treatment Plans to Improve Outcomes in Resectable NSCLC.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/3xb6WS1. CME/MOC credit will be available until June 14, 2023.
Chair & Moderator, Prof. Solange Peters, MD, PhD, Mark M. Awad, MD, PhD, and Jonathan D. Spicer, MD, PhD, FRCSC, prepared useful Practice Aids pertaining to Cancer Immunotherapy for this CME/MOC/CC activity titled “Parsing the Practicalities of Pathologic Response Assessment After Neoadjuvant Immunotherapy to Facilitate Progress in Early-Stage Cancers.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/CC information, and to apply for credit, please visit us at https://bit.ly/3uRHyjk. CME/MOC/CC credit will be available until May 9, 2023.
Robert Anders, MD, PhD, Julie R. Brahmer, MD, MSc, and Christopher D. Gocke, MD, prepared useful Practice Aids pertaining to immunotherapy and biomarker testing for this CME/MOC/CC activity titled "Keeping Up With Advances in Cancer Immunotherapy and Biomarker Testing: Implications for Pathologists at the Forefront of the Emerging Precision Immuno-Oncology Era." For the full presentation, monograph, complete CME/MOC/CC information, and to apply for credit, please visit us at http://bit.ly/2L7zlSy. CME/MOC/CC credit will be available until May 2, 2020.
Co-Chairs and Presenter Jessica Donington, MD, Jonathan D. Spicer, MD, PhD, FRCSC, and Patrick M. Forde, MD, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC/CC/AAPA activity titled “A Practical Guide for Making Multidisciplinary Decisions About Neoadjuvant and/or Adjuvant Immunotherapy in Resectable NSCLC.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at https://bit.ly/3MQVu5l. CME/MOC/CC/AAPA credit will be available until February 27, 2025.
This is a brief overview of the evolving field of prophylactic and therapeutic cancer vaccines.
Cancer vaccines are active immunotherapies. As seen in the accompanying figure, the distinction from passive immunotherapies is based on different mechanisms of action. Passive immunotherapies and adoptive T-cell transfer, for example, are made/modified outside of the body.
Once inside the body they can compensate for missing or deficient functions. Active immunotherapies, on the other hand, stimulate effector functions in vivo. What this means, is that the patient’s immune system can respond to the challenge and be stimulated to mediate effector cells that defend the body in an immune response. Examples of active immunotherapies include peptide, dendritic cell, and allogeneic whole-cell vaccines.
This intro is geared towards interested novices who wish to find a resource that can serve as a starting point for further self-study. This is not meant to replace a doctor's advice. Please approach a medical professional for any health condition.
Surviving and Thriving with Gynecologic Cancer - 9.29.18Summit Health
Gynecologic Oncology and wellness experts from Summit Medical Group MD Anderson Cancer Center in a special "brunch and learn" survivorship event for ovarian, cervical and other gynecologic cancer survivors. Moderated by Dr. Darlene Gibbon, Medical Director of Gynecologic Oncology, speaker-led sessions will present the promise of immunotherapy in treating gynecologic cancer; managing Menopause and other symptoms; and complementary medicine topics for women, including Acupuncture, Nutrition and Yoga.
Brendon Stiles, MD, Jamie E. Chaft, MD, and David H. Harpole Jr., MD, prepared useful Practice Aids pertaining to immunotherapy in earlier stages of lung cancer for this CME/MOC activity titled, "Immunotherapy as a Component of Multimodal Therapy in Locally Advanced and Earlier Stages of Lung Cancer: Rationale, Evidence, and Implications for the Multidisciplinary Team." For the full presentation, complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/2UnPFkF. CME/MOC credit will be available until June 24, 2021.
Brendon Stiles, MD, prepared useful practice aids pertaining to immunotherapy in earlier stages of lung cancer for this CME/MOC activity titled, "Chair's Take on Immunotherapy as a Component of Multimodal Therapy in Locally Advanced and Earlier Stages of Lung Cancer: Rationale, Evidence, and Implications for the Multidisciplinary Team." For the full presentation, monograph, complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/3dtEC0y. CME/MOC credit will be available until June 9, 2021.
The Potential for Individualization of Neoadjuvant Chemotherapy in Breast Can...CrimsonpublishersCancer
The preoperative, or, as it is often called, neoadjuvant chemotherapy (NAPCT) of operable breast cancer (the breast cancer) with affected regional lymph nodes has in its time replaced preoperative radiotherapy, as it has a number of significant advantages over the latter. The most important advantage of NAPCT is its systemic action, which allows to “catching up” with probable distant micro-metastases or circulating tumor cells, while pre-operative radiotherapy has a local effect, and on the systemic level the tumor continues to develop. Despite of the fact that with operative breast cancer the time of NAPCT (before or after the operation) does not affect to the long-term results of treatment, the latter becomes applicable even for operable breast cancer without affected regional lymph nodes.According to the literature, NAPCT with primary-operative breast cancer allows: 1) make organ saving operations; 2) improve the prognosis in cases of complete morphological regression in patients with triple negative and Her2 / neu positive (non-luminal) subtypes; 3) evaluate the effect of chemotherapy and, in the absence of effect, stop it on time [1].
Gastroenterology Medicine & Research-Crimson Publishers: Can we Optimize Immu...CrimsonGastroenterology
Immunotherapy is revolutionizing oncology, with a simple guiding principle: the host immune system has the potential to eradicate cancer, treatment consisting in optimizing immune actors' functions. Although significant results were demonstrated in patients with melanoma or lung cancer, objective response rate (ORR) is only 20% in digestive oncology. However, we can improve this situation by a better knowledge of anti-tumor immunity. For example, ORR is multiplied by two to three in case of PD-L1 (programmed death-ligand 1) overexpression or microsatellite instability (MSI). In a near future, we will certainly be able to take into account other biomarkers for building composite scores for assigning to each patient with digestive cancer an 'immune identity card' able to strongly predict immunotherapy efficacy.
Co-Chairs Riad Salem, MD, MBA, and Mark Yarchoan, MD, discuss liver cancer in this CME/MOC activity titled “Establishing the Collaborative Benchmark for HCC Care: Critical Discussions Between Interventional Radiologists and Oncologists to Maximize Therapeutic Benefit.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/3IOQvQ6. CME/MOC credit will be available until June 14, 2025.
Co-Chairs, Brett Elicker, MD, and David E. Griffith, MD, ATSF, ACCP, OFRSM, prepared useful Practice Aids pertaining to non-cystic fibrosis bronchiectasis for this CME/MOC activity titled “Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: Ensuring Prompt Diagnosis Through Accurate Interpretation of CT Imaging.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/48WUULu. CME/MOC credit will be available until June 4, 2025.
More Related Content
Similar to Can the Addition of Immunotherapy to Multimodal Management of Stage I-III NSCLC Help Break the Stalled Cycle of Poor Outcomes?
Surviving and Thriving with Gynecologic Cancer - 9.29.18Summit Health
Gynecologic Oncology and wellness experts from Summit Medical Group MD Anderson Cancer Center in a special "brunch and learn" survivorship event for ovarian, cervical and other gynecologic cancer survivors. Moderated by Dr. Darlene Gibbon, Medical Director of Gynecologic Oncology, speaker-led sessions will present the promise of immunotherapy in treating gynecologic cancer; managing Menopause and other symptoms; and complementary medicine topics for women, including Acupuncture, Nutrition and Yoga.
Brendon Stiles, MD, Jamie E. Chaft, MD, and David H. Harpole Jr., MD, prepared useful Practice Aids pertaining to immunotherapy in earlier stages of lung cancer for this CME/MOC activity titled, "Immunotherapy as a Component of Multimodal Therapy in Locally Advanced and Earlier Stages of Lung Cancer: Rationale, Evidence, and Implications for the Multidisciplinary Team." For the full presentation, complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/2UnPFkF. CME/MOC credit will be available until June 24, 2021.
Brendon Stiles, MD, prepared useful practice aids pertaining to immunotherapy in earlier stages of lung cancer for this CME/MOC activity titled, "Chair's Take on Immunotherapy as a Component of Multimodal Therapy in Locally Advanced and Earlier Stages of Lung Cancer: Rationale, Evidence, and Implications for the Multidisciplinary Team." For the full presentation, monograph, complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/3dtEC0y. CME/MOC credit will be available until June 9, 2021.
The Potential for Individualization of Neoadjuvant Chemotherapy in Breast Can...CrimsonpublishersCancer
The preoperative, or, as it is often called, neoadjuvant chemotherapy (NAPCT) of operable breast cancer (the breast cancer) with affected regional lymph nodes has in its time replaced preoperative radiotherapy, as it has a number of significant advantages over the latter. The most important advantage of NAPCT is its systemic action, which allows to “catching up” with probable distant micro-metastases or circulating tumor cells, while pre-operative radiotherapy has a local effect, and on the systemic level the tumor continues to develop. Despite of the fact that with operative breast cancer the time of NAPCT (before or after the operation) does not affect to the long-term results of treatment, the latter becomes applicable even for operable breast cancer without affected regional lymph nodes.According to the literature, NAPCT with primary-operative breast cancer allows: 1) make organ saving operations; 2) improve the prognosis in cases of complete morphological regression in patients with triple negative and Her2 / neu positive (non-luminal) subtypes; 3) evaluate the effect of chemotherapy and, in the absence of effect, stop it on time [1].
Gastroenterology Medicine & Research-Crimson Publishers: Can we Optimize Immu...CrimsonGastroenterology
Immunotherapy is revolutionizing oncology, with a simple guiding principle: the host immune system has the potential to eradicate cancer, treatment consisting in optimizing immune actors' functions. Although significant results were demonstrated in patients with melanoma or lung cancer, objective response rate (ORR) is only 20% in digestive oncology. However, we can improve this situation by a better knowledge of anti-tumor immunity. For example, ORR is multiplied by two to three in case of PD-L1 (programmed death-ligand 1) overexpression or microsatellite instability (MSI). In a near future, we will certainly be able to take into account other biomarkers for building composite scores for assigning to each patient with digestive cancer an 'immune identity card' able to strongly predict immunotherapy efficacy.
Co-Chairs Riad Salem, MD, MBA, and Mark Yarchoan, MD, discuss liver cancer in this CME/MOC activity titled “Establishing the Collaborative Benchmark for HCC Care: Critical Discussions Between Interventional Radiologists and Oncologists to Maximize Therapeutic Benefit.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/3IOQvQ6. CME/MOC credit will be available until June 14, 2025.
Co-Chairs, Brett Elicker, MD, and David E. Griffith, MD, ATSF, ACCP, OFRSM, prepared useful Practice Aids pertaining to non-cystic fibrosis bronchiectasis for this CME/MOC activity titled “Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: Ensuring Prompt Diagnosis Through Accurate Interpretation of CT Imaging.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/48WUULu. CME/MOC credit will be available until June 4, 2025.
Co-Chairs, Brett Elicker, MD, and David E. Griffith, MD, ATSF, ACCP, OFRSM, discuss non-cystic fibrosis bronchiectasis in this CME/MOC activity titled “Bridging the Gap to Improved Outcomes in Non-Cystic Fibrosis Bronchiectasis: Ensuring Prompt Diagnosis Through Accurate Interpretation of CT Imaging.” For the full presentation, downloadable Practice Aids, and complete CME/MOC information, and to apply for credit, please visit us at https://bit.ly/48WUULu. CME/MOC credit will be available until June 4, 2025.
Co-Chairs, Jonathan E. McConathy, MD, PhD, and Gil Rabinovici, MD, discuss Alzheimer's disease in this CME/AAPA activity titled “Applying Advances in PET Imaging to Facilitate the Early Diagnosis of Alzheimer’s Disease: Preparing Nuclear Medicine and Radiology Specialists for New Diagnostic Workflows.” For the full presentation, downloadable Practice Aids, and complete CME/AAPA information, and to apply for credit, please visit us at https://bit.ly/45RFl6g. CME/AAPA credit will be available until June 15, 2025.
Co-Chairs Sarah Hayward, PharmD, BCOP, and Ambar Khan, PharmD, BCOP, discuss endometrial and cervical cancers in this CME/CPE/IPCE activity titled “A Pharmacist’s Take on Navigating the Expanding Therapeutic Landscape for Endometrial and Cervical Cancers: Insights on Coordinating and Delivering Effective Modern Care.” For the full presentation, downloadable Practice Aids, and complete CME/CPE/IPCE information, and to apply for credit, please visit us at https://bit.ly/3wGBPQp. CME/CPE/IPCE credit will be available until May 27, 2025.
Co-Chairs, Suzanne Lentzsch, MD, PhD, and Joshua Richter, MD, discuss multiple myeloma in this CME activity titled “‘Four-Ward’ Progress in NDMM: New Developments With CD38 Antibody Quadruplets.” For the full presentation and complete CME information, and to apply for credit, please visit us at https://bit.ly/3x3oWA3. CME credit will be available until May 23, 2025.
Co-Chairs, Jessica Donington, MD, and Jonathan D. Spicer, MD, PhD, FRCSC, prepared useful Practice Aids pertaining to lung cancer for this CME/MOC/AAPA activity titled “Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable NSCLC: A Case Exploration of New Standards and Emerging Approaches.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/3TxdcP5. CME/MOC/AAPA credit will be available until June 7, 2025.
Co-Chairs, Jessica Donington, MD, and Jonathan D. Spicer, MD, PhD, FRCSC, discuss lung cancer in this CME/MOC/AAPA activity titled “Transforming Care and Outcomes With Immunotherapy in Stage I-III Resectable NSCLC: A Case Exploration of New Standards and Emerging Approaches.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/3TxdcP5. CME/MOC/AAPA credit will be available until June 7, 2025.
Chair Oliver Sartor, MD, discusses prostate cancer in this CME activity titled “On Target: Understanding the Impact of PSMA for Diagnostic and Therapeutic Strategies in Prostate Cancer.” For the full presentation, downloadable Practice Aids, and complete CME information, and to apply for credit, please visit us at https://bit.ly/49oY4IJ. CME credit will be available until May 23, 2025.
Chair and Presenters, Neal D. Shore, MD, FACS, Ashish M. Kamat, MD, MBBS, and Joshua J. Meeks, MD, PhD, prepared useful Practice Aids pertaining to bladder cancer for this CME/MOC/NCPD/AAPA/IPCE activity titled “Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Implementing Modern Therapeutic Advances Across the Disease Continuum.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3PH0RVQ. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 2, 2025.
Chair and Presenters, Neal D. Shore, MD, FACS, Ashish M. Kamat, MD, MBBS, and Joshua J. Meeks, MD, PhD, discuss bladder cancer in this CME/MOC/NCPD/AAPA/IPCE activity titled “Harnessing Innovation in Bladder Cancer Care: Strategies for Effectively Implementing Modern Therapeutic Advances Across the Disease Continuum.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3PH0RVQ. CME/MOC/NCPD/AAPA/IPCE credit will be available until June 2, 2025.
Chair, Nicholas J. Short, MD, discusses acute lymphoblastic leukemia in this CME/NCPD/CPE/AAPA/IPCE activity titled “Striking Back at ALL: Achieving Lasting Benefits with Bispecific Antibodies & MRD-Guided Strategies Across Disease Settings.” For the full presentation, downloadable Practice Aids, and complete CME/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/42QsTDT. CME/NCPD/CPE/AAPA/IPCE credit will be available until May 22, 2025.
Chair, Sharon Cohen, MD, FRCPC, prepared useful Practice Aids pertaining to Alzheimer’s disease for this CME/MOC/AAPA activity titled “Specialty Training for the New Era in Alzheimer’s Disease: Building Skills for Making an Early Diagnosis and Implementing Disease-Modifying Treatment.” For the full presentation, downloadable Practice Aids, monograph, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/472bp8g. CME/MOC/AAPA credit will be available until May 20, 2025.
Chair, Sharon Cohen, MD, FRCPC, discusses Alzheimer’s disease in this CME/MOC/AAPA activity titled “Specialty Training for the New Era in Alzheimer’s Disease: Building Skills for Making an Early Diagnosis and Implementing Disease-Modifying Treatment.” For the full presentation, downloadable Practice Aids, monograph, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at https://bit.ly/472bp8g. CME/MOC/AAPA credit will be available until May 20, 2025.
Chair and Presenter, Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO, Donna D. Catamero, ANP-BC, OCN, CCRC, and Charise Gleason, MSN, NP-C, AOCNP, discuss multiple myeloma in this CME/MOC/NCPD/ILNA/IPCE activity titled “Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remission With Antibodies, BCMA Immunotherapy, and Other Innovations.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at https://bit.ly/47mtUnM. CME/MOC/NCPD/ILNA/IPCE credit will be available until May 25, 2025.
Co-Chairs and Presenter Marianne Davies, DNP, ACNP, AOCNP, FAAN, Beth Sandy, MSN, CRNP, FAPO, and Matthew A. Gubens, MD, MS, FASCO, prepared useful Practice Aids pertaining to NSCLC for this CME/MOC/NCPD/ILNA/IPCE activity titled “Making Patient-Centric Immunotherapy a Reality in Lung Cancer: Best Practices for Patient Education, irAE Management, and Survivorship Care.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3RDokbZ. CME/MOC/NCPD/ILNA/IPCE credit will be available until May 24, 2025.
Co-Chairs and Presenter Marianne Davies, DNP, ACNP, AOCNP, FAAN, Beth Sandy, MSN, CRNP, FAPO, and Matthew A. Gubens, MD, MS, FASCO, discuss NSCLC in this CME/MOC/NCPD/ILNA/IPCE activity titled “Making Patient-Centric Immunotherapy a Reality in Lung Cancer: Best Practices for Patient Education, irAE Management, and Survivorship Care.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/ILNA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3RDokbZ. CME/MOC/NCPD/ILNA/IPCE credit will be available until May 24, 2025.
Co-Chairs, Sia Daneshmand, MD, and Matthew D. Galsky, MD, discuss bladder cancer in this CME/MOC/NCPD/AAPA/IPCE activity titled “Modern Team-Based Therapeutic Management for Bladder Cancer Care: Expert Strategies for Integrating the Latest Evidence and Treatment Advances.” For the full presentation, downloadable Practice Aids, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at https://bit.ly/3OOeYbO. CME/MOC/NCPD/AAPA/IPCE credit will be available until May 13, 2025.
Chair Jamie Carroll, APRN, CNP, MSN, discusses breast cancer in this NCPD/ILNA/AAPA activity titled “Nurses at the Forefront of Maximizing the Potential of TROP2-Targeted Therapy in TNBC and HR+, HER2- Breast Cancer: Best Practices for Adverse Event Management and Patient Education.” For the full presentation, downloadable Practice Aids, and complete NCPD/ILNA/AAPA information, and to apply for credit, please visit us at https://bit.ly/3SdnvWt. NCPD/ILNA/AAPA credit will be available until May 8, 2025.
Chair Jonathan A. Bernstein, MD, discusses chronic spontaneous urticaria in this CME activity titled “BTK Inhibition Transforming the Landscape of Chronic Spontaneous Urticaria Treatment.” For the full presentation, downloadable Practice Aids, and complete CME information, and to apply for credit, please visit us at https://bit.ly/3P0cnvi. CME credit will be available until May 6, 2025.
More from PVI, PeerView Institute for Medical Education (20)
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Can the Addition of Immunotherapy to Multimodal Management of Stage I-III NSCLC Help Break the Stalled Cycle of Poor Outcomes?
1. Immune Checkpoint Inhibition
Harnessing the Immune System in the Treatment of Cancer
Full abbreviations, accreditation, and disclosure information available at
PeerView.com/CRA40
Tumor Microenvironment
Lymphoid Tissue
Immune checkpoint inhibitors modulate T-lymphocyte responses
against cancer by blocking negative regulation of immune responses
PD-1 pathway inhibits
signaling downstream of TCR
•
TCR triggered by antigen
presented by tumor cell
• Negative regulatory receptor
PD-1 expressed and PD-L1
reactively expressed
• PD-L1 binds to PD-1
T cell inactivated
T cell inactivated
T cell activated
T cell activated
Anti–PD-1 or anti–PD-L1
monoclonal antibodies
block the interaction and
negative regulation
Anti–CTLA-4 monoclonal
antibodies block negative
regulation by CTLA-4
CTLA-4 is a negative regulator
of costimulation required for
activation of an
antitumor T cell in a lymph
node upon recognition of
tumor antigen
PD-1/PD-L1
Checkpoint
Inhibition
CTLA-4
Checkpoint
Inhibition
FDA-Approved Therapies
FDA-Approved Therapies
GO
Tumor escape
Tumor escape
Tumor attack
Tumor attack
Anti–PD-1: Nivolumab
Pembrolizumab
Cemiplimab-rwlc
Anti–CTLA-4: Ipilimumab
Anti–PD-L1: Atezolizumab
Avelumab
Durvalumab
•
Proteins on T cells or cancer cells that need to be activated/inactivated to start/stop
an immune response (eg, PD-1, PD-L1, CTLA-4)
•
Serve as “brakes” that help keep immune responses in check; can prevent T-cell response
against cancer cells
•
Can be blocked by immune checkpoint inhibitors (the “brakes” on the immune system are
released and T cells are able to attack and kill cancer cells)
What Are
Immune
Checkpoints?
Tumor Microenvironment
Elimination of tumor cells
Tumor escape
With
Immunotherapy
Without
Immunotherapy
PD-1/PD-L1 Checkpoint Inhibition
Elimination of tumor cells
Tumor escape
CTLA-4 Checkpoint Inhibition
With
Immunotherapy
Without
Immunotherapy
Lymphoid Tissue
2. Expanding Role and Use of Neoadjuvant and Adjuvant
Immunotherapy in Resectable Solid Tumors
Rationale and Current Approvals/Indications
Full abbreviations, accreditation, and disclosure information available at PeerView.com/CRA40
Neoadjuvant immunotherapy is administered before surgery and can reduce the
size of the primary tumor as well as eliminate residual cancers cells left after surgery
Rationale:
• Lower disease burden and intact
immune system
• T-cell response generated against
in situ primary tumor with diverse
antigen load
• Fast endpoints to assess response
• Allows for translational research:
biologic and immunologic
correlative studies
Rationale:
• Lower disease burden and intact
immune system
• Immunological pathways are
disrupted by surgical stress
• No risk for delaying surgery with
adjuvant versus neoadjuvant
approach
• Prior chemotherapy or other
systemic/local therapies may help
augment immune responses
Adjuvant immunotherapy is administered after surgery and leads to an increase
in activated T cells that can eliminate residual cancer cells in the tumor bed
Comparison of adjuvant and neoadjuvant immunotherapy treatment approaches1
Immunotherapy
T cells
T-cell activation Resection surgery
Solid tumor Resection surgery Immunotherapy T-cell activation
and additional
immunotherapy
Tumor cells Artery Healthy cells Immunotherapy
3. Expanding Role and Use of Neoadjuvant and Adjuvant
Immunotherapy in Resectable Solid Tumors
Rationale and Current Approvals/Indications
Full abbreviations, accreditation, and disclosure information available at PeerView.com/CRA40
Overall survival (OS) is the gold-standard outcome measure for phase 3 trials, but the protracted length of these
clinical trials in resectable cancers makes this research daunting and expensive
One strategy to expedite clinical trials, including those assessing immunotherapies in early-stage cancer settings,
is the use of newer, innovative surrogate measurements for endpoints
Because pathologic response reflects a therapy’s ability to eradicate tumor cells more directly than radiographic
evaluation using RECIST criteria, it may better correlate with clinically meaningful outcomes
Several trials in different tumor types have correlated the novel endpoints with more traditional endpoints such as OS,
DFS, and RFS, but additional confirmatory studies are needed
Many adjuvant approvals have been based on disease-free survival (DFS)
Trials in neoadjuvant settings provide an opportunity to assess pathologic response as an early surrogate marker
for survival outcomes, and pathologic response criteria such as major pathological response (MPR) and pathologic
complete response (pCR) have been assessed in neoadjuvant immunotherapy trials; there are various definitions,
but generally:
MPR: ≤10% of viable tumor in the treated tumor bed
pCR: complete absence of viable tumor in the treated tumor bed
Recently, immune-related pathologic response criteria (irPRC) have also been developed with the aim of assessing
the full spectrum of response to immunotherapy in resection specimens
Different scoring systems exist or are in development for evaluating pathologic response in various tumor types
(eg, melanoma, lung cancer, bladder cancer)
Relevant endpoints for neoadjuvant and adjuvant immunotherapy clinical trials2-8
4. Expanding Role and Use of Neoadjuvant and Adjuvant
Immunotherapy in Resectable Solid Tumors
Rationale and Current Approvals/Indications
Full abbreviations, accreditation, and disclosure information available at PeerView.com/CRA40
Adjuvant treatment of patients with urothelial carcinoma who are at high risk of recurrence after undergoing
radical resection
Adjuvant treatment of patients with completely resected esophageal or gastroesophageal junction cancer with
residual pathologic disease who have received neoadjuvant chemoradiotherapy
Adjuvant treatment of patients with melanoma with lymph node involvement or metastatic disease who have
undergone complete resection
Current perioperative approvals and indications of immunotherapies in solid tumors9
Nivolumab
Adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of
more than 1 mm who have undergone complete resection, including total lymphadenectomy
Ipilimumab
5. Expanding Role and Use of Neoadjuvant and Adjuvant
Immunotherapy in Resectable Solid Tumors
Rationale and Current Approvals/Indications
Full abbreviations, accreditation, and disclosure information available at PeerView.com/CRA40
Neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer with chemotherapy adjuvant treatment
after surgery as a single agent
Adjuvant treatment of patients with renal cell carcinoma at intermediate-to-high or high risk of recurrence following
nephrectomy, or following nephrectomy and resection of metastatic lesions
Adjuvant treatment of patients with stage IIB, IIC, or III melanoma following complete resection
Patients with BCG-unresponsive, high-risk, non–muscle invasive bladder cancer with carcinoma in situ with or without
papillary tumors who are ineligible for or have elected not to undergo cystectomy
Current perioperative approvals and indications of immunotherapies in solid tumors9
Pembrolizumab
Adjuvant treatment following resection and platinum-based chemotherapy in patients with stage II to IIIA non–small
cell lung cancer whose tumors have PD-L1 expression on ≥1% of tumor cells
Atezolizumab
1. Krishnamoorthy M et al. J Natl Cancer Inst. 2021;113:823-832. 2. Topalian SL et al. Science 2020;367:eaax0182. 3. Benitez JC et al. Clin Cancer Res. 2020;26:5068-5077. 4. Bilusic M, Gulley JL. J Natl Cancer Inst. 2021;113:799-800. 5. Krishnamoorthy M et al. J Natl Cancer Inst. 2021;113:823-
832. 6. O’Donnell JS et al. Clin Cancer Res. 2019;25:5743-5751. 7. Hellmann MD et al. Lancet Oncol. 2014;15:e42-50. 8. Cottrell TR et al. Ann Oncol. 2018;29:1853-1860. 9. https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-
approval-notifications.
6. Immune-Related Adverse Events of Cancer Immunotherapies
Become Aware and Stay Vigilant1-4
Full abbreviations, accreditation, and disclosure information available at PeerView.com/CRA40
What Are irAEs?
• Immune checkpoint inhibitors are associated with important clinical benefits, but general immunologic enhancement
can also lead to a unique spectrum of immune-related adverse events
• Any organ system can be affected, but more commonly occurring are pulmonary (pneumonitis), dermatologic (rash, pruritus,
blisters, ulcers, vitiligo), gastrointestinal (diarrhea, enterocolitis, transaminitis, hepatitis, pancreatitis), and endocrine
(thyroiditis, hypophysitis, adrenal insufficiency) irAEs
Endocrine
Hyper- or hypothyroidism
Hypophysitis
Adrenal insufficiency
Diabetes
Hepatic
Hepatitis
Renal
Nephritis
Dermatologic
Rash
Pruritus
Psoriasis
Vitiligo
DRESS
Stevens-Johnson
Hematologic
Hemolytic anemia
Thrombocytopenia
Neutropenia
Hemophilia
Ocular
Uveitis
Conjunctivitis
Scleritis, episcleritis
Blepharitis
Retinitis
Respiratory
Pneumonitis
Pleuritis
Sarcoid-like granulomatosis
Cardiovascular
Myocarditis
Pericarditis
Vasculitis
Gastrointestinal
Colitis
Ileitis
Pancreatitis
Gastritis
Neurologic
Neuropathy
Guillain Barŕe
Myelopathy
Encephalitis
Myasthenia
Musculoskeletal
Arthritis
Dermatomyositis
Prevention Anticipation
Treatment
Monitoring Detection
7. Immune-Related Adverse Events of Cancer Immunotherapies
Become Aware and Stay Vigilant1-4
Full abbreviations, accreditation, and disclosure information available at PeerView.com/CRA40
Guidance for Surgeons: Suspect, Detect, and Refer for Treatment5,6
• irAEs frequently occur in the perioperative setting, either before or after surgical intervention
• irAEs occurring during neoadjuvant immunotherapy are generally manageable and in most cases should not exclude
patients from surgery
• The onus is on the surgeon to have a high degree of suspicion for potential toxicities in patients treated with immunotherapy
• Vague symptoms should not be dismissed, because nonspecific ailments can be indicative of severe toxicity
– Rheumatologic toxicities and endocrinopathies are some of the most difficult to recognize, given their relatively
nonspecific presentation
» For example, fatigue, poor energy, and low mood could represent hypophysitis or adrenal insufficiency
– Other toxicities can be essentially asymptomatic
» For example, renal and hepatic toxicity are generally only detected on routine labs
– Pneumonitis is another relevant irAE requiring awareness by surgeons, as severe pneumonitis could potentially
exclude patients from operative therapy, but significant pneumonitis has been rare in trials to date
• A comprehensive workup for irAEs, with a thorough history specifically targeted to potential irAEs, should be conducted
• Coordinate and collaborate with oncologists and other multidisciplinary experts to optimally diagnose and manage irAEs
in patients who have received/are receiving perioperative immunotherapy
• The National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) have issued
guidelines for recognition and management of immune-related adverse events
8. How Should irAEs Be Diagnosed and Managed?
Minimal or No Symptoms; Diagnostic Changes Only
• In general, immunotherapy should be continued with close monitoring, with the exception of some neurologic, hematologic, and
cardiac toxicities
Mild to Moderate Symptoms
• Hold checkpoint inhibitor therapy for most grade 2 toxicities
• Consider resuming immunotherapy when symptoms and/or lab values revert to grade 1
• Corticosteroids (initial dose of 0.5-1.0 mg/kg/day of prednisone or equivalent) may be administered
Severe or Life-Threatening Symptoms
Grade 3 toxicities
• Hold checkpoint inhibitor therapy
• Initiate high-dose corticosteroids (prednisone 1-2 mg/kg/day or methylprednisolone IV 1-2 mg/kg/day)
• If symptoms do not improve with 48-72 hours of high-dose corticosteroid, infliximab may be offered for some toxicities
• Taper corticosteroids over the course of at least 4-6 weeks
• When symptoms and/or laboratory values revert to grade 1, rechallenging with immunotherapy may be considered; however,
caution is advised, especially in those patients with early-onset irAEs; dose adjustments are not recommended
Grade 4 toxicities
• In general, permanent discontinuation of checkpoint inhibitor therapy is warranted, with the exception of endocrinopathies that have
been controlled by hormone replacement
irAEs are often
diagnosed by exclusion;
other causes should be
ruled out (including AEs
of other therapies used),
but immunotherapy-related
toxicity should always be
included in the differential
There should be a high
level of suspicion that
new symptoms are
treatment related; early
recognition, evaluation,
and treatment of irAEs
plus patient education
are essential for the
best outcome
Depending on severity
of irAE, management
may require
corticosteroid or other
immunosuppressive
treatment and
interruption or
discontinuation of therapy
If appropriate
immunosuppressive
treatment is
used, patients generally
recover from irAEs
Use of immunosuppressive
therapy to manage
irAEs does not appear to
impact response to
immunotherapy
Grade 1
Grade 2
Grade 3/4
Immune-Related Adverse Events of Cancer Immunotherapies
Become Aware and Stay Vigilant1-4
Full abbreviations, accreditation, and disclosure information available at PeerView.com/CRA40
9. Hold immunotherapy with radiographic evidence of pneumonitis progression
May offer one repeat CT in 3-4 weeks; in patients who have had baseline testing, may offer a repeat
spirometry/DLCO in 3-4 weeks
May resume immunotherapy with radiographic evidence of improvement or resolution; if no improvement,
should treat as grade 2
Monitor patients weekly with history, physical examination, and pulse oximetry; may also offer CXR
Grade 2: Symptomatic; 1 lobe
of lung or 25%-50% of lung
parenchyma; medical intervention
indicated; limiting instrumental ADL
Grade 3: Severe symptoms
requiring hospitalization; involves
all lung lobes or 50% of lung
parenchyma; limiting self care
Grade 4: Life-threatening
respiratory compromise; urgent
intervention indicated (intubation)
Hold immunotherapy until resolution to grade ≤1
Prednisone 1-2 mg/kg/day and taper by 5-10 mg/week over 4-6 weeks
Consider bronchoscopy with BAL
Consider empiric antibiotics
Monitor patients every 3 days with history, physical examination, and pulse oximetry; consider CXR; if no clinical
improvement after 48-72 hours of prednisone, treat as grade 3
Discontinue immunotherapy
Empiric antibiotics; methylprednisolone IV 1-2 mg/kg/day; if no improvement after 48 hours, may add infliximab
5 mg/kg, or mycophenolate mofetil IV 1 g 2x/day, or IVIG x 5 days, or cyclophosphamide
Taper corticosteroids over 4-6 weeks
Pulmonary and infectious disease consults if necessary
Bronchoscopy with BAL +/- transbronchial biopsy
Patients should be hospitalized for further management
How Should Pulmonary irAEs Be Diagnosed and Managed?
Pneumonitis: focal or diffuse inflammation of the lung parenchyma (typically identified on CT imaging)
Diagnostic work-up: CXR, CT, pulse oximetry; for grade ≥2, may include infectious work-up
Grade 1: Asymptomatic; confined
to 1 lobe of lung or 25% of lung
parenchyma; clinical or diagnostic
observations only
Additional considerations
• GI and pneumocystis prophylaxis may be offered to patients on prolonged steroid use (12 weeks)
• Consider calcium and vitamin D supplementation with prolonged steroid use
• Bronchoscopy + biopsy; if clinical picture is consistent with pneumonitis, no need for biopsy
Immune-Related Adverse Events of Cancer Immunotherapies
Become Aware and Stay Vigilant1-4
Full abbreviations, accreditation, and disclosure information available at PeerView.com/CRA40
1. Brahmer JR et al. J Clin Oncol. 2018;36:1714-1786. 2. Postow MA et al. N Engl J Med. 2018;378:158-168. 3. Gordon R et al. Clin J Oncol Nurs. 2017;21(suppl 2):45-52. 4. Champiat S et al. Ann Oncol. 2016;27:559-574. 5. Helmink BA et al. Ann Surg Oncol. 2020;27:1533-1545.
6. Stiles BM et al. J Thorac Cardiovasc Surg. 2020;160:1376-1382.